921 results about "Bowels diseases" patented technology

This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.

The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.

The invention discloses an attenuated artificial bear gall powder nano preparation, the physical structure of which is a core-shell structure, the core is zinc oxide nanoparticles, the shell is mesoporous SiO2, and artificial bear gall powder is attached to the outer surface of the shell, through the design of the core-shell structure, the dissolution of zinc ions can be reduced while efficient loading and pH response release of the artificial bear gall powder can be realized, and the toxicity of the artificial bear gall powder can be reduced. The toxicity of the preparation is reduced; the invention further discloses a preparation method which has the characteristics of simple steps, low cost and suitability for industrial production. The invention further discloses a novel application range, namely, the compound has a wide clinical application prospect in the fields of inflammatory bowel diseases and the like needing targeted anti-inflammatory treatment.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and / or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

This invention discloses a system for predicting the efficacy of inflammatory bowel disease based on multimodal data, relating to the field of medical information processing. The system includes: a multimodal data acquisition module for receiving multimodal data; a text feature extraction module for determining text feature vectors using a text feature extraction model; an endoscopic intestinal mucosal feature recognition module for determining intestinal mucosal features using an endoscopic intestinal mucosal feature recognition model; an image feature recognition module for determining imaging features using an image feature recognition model; a pathological feature extraction module for determining pathological features using a pathological recognition model; and an efficacy prediction module for predicting the efficacy of biologics based on multimodal data features using a Transformer model and fully connected layers. Compared to existing technologies, this invention achieves efficacy prediction of biologics based on the fusion of clinical, pathological, endoscopic, and imaging multimodal features, improving the accuracy and clinical rationality of diagnostic and treatment decisions.

The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.

Compositions and methods for detecting gastrointestinal diseases are provided. The present invention relates to compositions and methods for detecting and treating gastrointestinal diseases. The present invention relates to the use of an agent for determining intestinal alkaline phosphatase (iAP) activity and the amount of iAP in a child for the preparation of a kit for use in a method for determining the prognosis of inflammatory bowel disease (IBD) in said child.

The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).

The invention discloses lactobacillus kefiranofaciens and application thereof, and belongs to the technical field of microorganisms. The strain number of the lactobacillus kefiranofaciens is 2503, the lactobacillus kefiranofaciens is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number of the lactobacillus kefiranofaciens is CGMCC NO.33828. The lactobacillus kefiranofaciens is named as Lactobacillus kefiranofaciens. The lactobacillus kefiranofaciens provided by the invention is strong in acid resistance and bile salt resistance, has the functions of resisting oxidation and scavenging free radicals, can be planted in intestinal tracts, improves the abundance of beneficial bacteria in the intestinal tracts and reduces the abundance of pathogenic bacteria, and has good prevention and treatment effects on inflammatory bowel diseases.

The present invention provides the application of lily polysaccharide in the preparation of drugs for treating inflammatory bowel disease, and relates to the field of new drug uses. Lily polysaccharide can improve inflammatory bowel disease by regulating the differentiation of CD4+ T cells, and has broad application prospects in the development of new targeted drugs.

The invention discloses a preparation method and application of a targeted delivery system of a metal polyphenol nano system. The invention discloses a targeted delivery system of a metal polyphenol nano system, and a preparation method of the targeted delivery system comprises the following steps: taking the metal polyphenol nano system formed based on epigallocatechin gallate and iron ions as a carrier, and loading fucoxanthin to prepare fucoxanthin nano particles with active oxygen response characteristics; then, after chondroitin sulfate capable of targeting macrophages and (5-carboxyl amyl) triphenyl phosphorus bromide capable of targeting mitochondria are coupled, the fucoxanthin delivery system with the active oxygen response characteristic and the targeting characteristic is further prepared through a double emulsion anti-solvent evaporation method. The system can realize release of fucoxanthin under stimulation of active oxygen, and realizes aggregation of a targeted delivery system in mitochondria of a specific inflammation site. The carrying system can effectively improve or relieve the inflammatory bowel disease, and the raw materials used in the carrying system are low in cost, the preparation conditions are mild, and large-scale production is easy.

The invention discloses lactobacillus rhamnosus 1.0320, a metagen as well as a preparation method and application of the lactobacillus rhamnosus 1.0320 and the metagen, and belongs to the technical field of microorganisms. The invention provides lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on April 8, 2018, and the preservation number of the lactobacillus rhamnosus 1.0320 is CGMCC (China General Microbiological Culture Collection Center) NO.15557. The lactobacillus rhamnosus 1.0320 can be used for preparing the lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 and the metagen thereof provided by the invention have the effects of improving the intestinal barrier and relieving the inflammatory bowel disease.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

The invention relates to the technical field of microorganisms, and discloses Ackermann muciniphila, a combined microbial agent thereof and application of the Ackermann muciniphila in inflammatory enteritis. The invention provides Akkermansia muciniphila AIML-559, and the preservation number of the Akkermansia muciniphila AIML-559 is CGMCC (China General Microbiological Culture Collection Center) No. 34246. The invention relates to a combined microbial agent, which is characterized by comprising Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34300). The combined microbial agent is prepared from the following raw materials: Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 The ackermann mucophil combined microbial inoculum is suitable for treatment intervention of inflammatory bowel disease (IBD), and can relieve weight loss, hemolysis, anemia, diarrhea, intestinal bleeding and other symptoms of IBD mice.

The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and / or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and / or prevention of inflammatory diseases, in particular, inflammatory bowel disease.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

The invention discloses application of lanthanum carbonate in treatment of inflammatory bowel diseases, lanthanum carbonate achieves the effect of treating inflammatory diseases by depriving cfDNA, eATP and other proinflammatory factors generated at an inflammatory part, and symptoms induced by IBD are effectively relieved. The lanthanum carbonate disclosed by the invention has a strong cfDNA and eATP removal function, has good biocompatibility, has no direct or indirect toxic action on a human body, has no potential toxicity, and can be used for treating inflammatory bowel diseases.

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention discloses a multi-layer multi-release metagen composition and application thereof in quickly promoting defecation, lubricating intestinal tracts, relieving intestinal problems such as flatulence, stomachache, diarrhea, constipation, irritable bowel syndrome and inflammatory bowel disease, maintaining intestinal flora balance, repairing intestinal tracts, repairing intestinal mucosa health, relieving dyspepsia and improving gastrointestinal functions.

The present invention provides a pharmaceutical composition having an effective dose of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof for treating inflammatory bowel disease. Disclosed is a pharmaceutical composition for treating inflammatory bowel disease, which comprises a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, where the compound or the pharmaceutically acceptable salt thereof is administered to a human at a dose of 50 mg or more per day as an active ingredient, where R represents a hydroxyl group or an isobutoxy group.